Stock AnalizSpyre Therapeutics, Inc. SYRE
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Spyre Therapeutics, Inc. (SYRE) is a healthcare company listed in the US with a market value of about $9.9B.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -81%.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886000 | $2M | $19M | $0 | $0 | $4M | $5M | $5M |
| Net income | -$155M | -$208M | -$339M | -$84M | -$66M | -$81M | -$78M | -$44M | -$27M | -$22M |
| Free cash flow | — | -$157M | -$100M | -$80M | -$54M | -$80M | -$67M | -$33M | -$25M | -$19M |
| EPS (diluted) | $-1.63 | — | $13.76 | $-24.86 | $-25.02 | $-38.00 | $-61.25 | $-53.25 | $-45.00 | $-55.50 |
| Net margin | — | — | -38238.2% | -3598.7% | -351.1% | — | — | -1140.6% | -523.3% | -468.8% |
| ROIC | -29.3% | -31.8% | -131.7% | -154.1% | -58.3% | -56.1% | -123.3% | -53.3% | -43.4% | -27.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $122.67, 18% above the current price; targets range from $114.00 to $135.00; the consensus rating is “Strong buy”; expected EPS is $-3.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Spyre Therapeutics pay a dividend?
Not currently.
Is Spyre Therapeutics a good stock to buy?
We do not give buy or sell advice. Spyre Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.